Partnering
We partner to deliver best-in-class treatment options to patients
We engage with partners so we can focus on our core competencies. Zealand’s strength lies in therapeutic peptide discovery, design and development, which has led to our R&D pipeline of differentiated candidates targeting obesity, rare diseases, and chronic inflammation.
Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities to deliver new therapies to patients with unmet medical needs.
We engage with partners across the value chain. We also have partnerships with leading academic and scientific institutions, contract research organizations (CROs), contract manufacturing and development organizations (CDMOs), and distribution partners.
Our partners
Boehringer Ingelheim
In 2011, Zealand Pharma and Boehringer Ingelheim partnered to develop drug candidates for type 2 diabetes and obesity. As part of the agreement, survodutide, a long-acting glucagon/GLP-1 receptor dual agonist, is licensed to Boehringer Ingelheim.
Survodutide is being developed for the treatment of obesity and MASH, with Boehringer Ingelheim solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). Zealand Pharma is eligible to receive up to EUR 315 million in outstanding milestone payments, plus tiered royalties ranging from high single-digit to low double-digit percentages on potential global sales by Boehringer Ingelheim.
Visit website
Novo Nordisk
In 2022, Zealand Pharma and Novo Nordisk entered into a global partnership for commercializing dasiglucagon for injection, approved in 2021 by the U.S. Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above.
Under the terms of the license and development agreement, Zealand received an upfront payment of DKK 25 million. Zealand is eligible to receive up to DKK 22.5 million in remaining development milestones and DKK 220.0 million in sales-based milestones as well as tiered royalties ranging from high single-digit to low double-digit percentages on worldwide net sales of the product by Novo Nordisk. Zealand is responsible for certain planned regulatory, development and manufacturing activities to support approval outside of the U.S. Zealand is also eligible for compensation on a time and material basis for certain product supply, research and development services delivered under the contract.
Visit website
DEKA Research & Development Corp
In 2021, Zealand partnered with DEKA Research & Development Corp. and affiliates to develop a continuous infusion pump to be used in combination with dasiglucagon, an investigational agent designed for patients living with congenital hyperinsulinism. The agreement covers the technical development of the pump system as well as associated manufacturing and commercialization activities.
Visit websiteAccessing cutting-edge technology through research collaborations
We also have an interest in novel ideas for biological targets which could be addressed with peptide therapeutics as well as novel peptide chemistry.
In addition, we are focused on identifying novel technologies that allow alternative routes of administration, improve drug-like properties, and facilitate conjugation of additional moieties to peptides.
